FOR IMMEDIATE RELEASE: May 31, 2010
Wendy Isett, AUA
NEW BPH AND BLADDER CANCER TREATMENT DELIVERY MECHANISMS SUCCESSFUL
Two new treatment delivery methods improved post-treatment outcomes for bladder cancer patients and improved symptoms of LUTS patients
San Francisco, CA, May 31, 2010–Baseline prostate-specific antigen (PSA) and prostate volume can be valuable predictors of treatment success when considering botulinum toxin-A (BoNT-A or Botox®) therapy for the treatment of lower urinary tract symptoms (LUTS), according to a new study being presented today at the 105th Annual Meeting of the American Urological Association (AUA). Data will be presented to the media during a special press conference on Monday, May 31, 2010 at 8:30 a.m. PDT.
This multi-center, Phase II study explored whether assessing prostate volume and PSA score impacted the effectiveness of BoNT-A injection to treat LUTS in 134 men aged 50 and older. Men were randomized to receive 100 or 300 units of BoNT-A, and follow-up was taken at four, eight and 12 weeks, and also at one year. Follow up included prostate volume, serum PSA, AUA Symptom Score, BPH II, Qmax and post-void residual (PVR) volume.
Of the participants, 63 of 67 were given 100 units of BoNT-A, while 53 of 55 were given 300 units. Researchers noticed significant changes in AUA symptom scores and peak urinary flow rates at three and 12 months after treatment, without seeing significant changes in prostate volume or PSA. The greatest response in symptoms occurred in those with the lowest PSA scores.
“This study shows that Botox® treatment for LUTS may not be as effective in men with larger prostates and higher PSA levels,” said Anthony Y. Smith, an AUA spokesman. “We can use this information to better assess which men can benefit most from this treatment.”
NOTE TO REPORTERS: Experts are available to discuss this study outside normal briefing times. To arrange an interview with an expert, please contact the AUA Communications Office at the number above or e-mail Communications@AUAnet.org.
About the American Urological Association: Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is the pre-eminent professional organization for urologists, with more than 16,000 members throughout the world. An educational nonprofit organization, the AUA pursues its mission of fostering the highest standards of urologic care by carrying out a wide variety of programs for members and their patients.